key: cord-0780705-fbyq0nco
authors: Brodard, Justine; Kremer Hovinga, Johanna A.; Fontana, Pierre; Studt, Jan‐Dirk; Gruel, Yves; Greinacher, Andreas
title: COVID‐19 patients often show high‐titer non‐platelet‐activating anti‐PF4/heparin IgG antibodies
date: 2021-02-07
journal: J Thromb Haemost
DOI: 10.1111/jth.15262
sha: 5ac8d13e6a941ba3b8b18929e1c8c1ac4708050b
doc_id: 780705
cord_uid: fbyq0nco

BACKGROUND: Heparin‐induced thrombocytopenia (HIT) is a severe adverse reaction to heparin caused by heparin‐dependent, platelet activating anti‐platelet factor 4 (PF4)/heparin antibodies. Heparin is a cornerstone of treatment in critically ill COVID‐19 patients. HIT antibodies can be detected by antigen tests and functional tests. Often strong reactivity in the antigen test is used as surrogate marker for the presence of clinically relevant, platelet activating antibodies. We observed an unexpectedly high percentage of COVID‐19 patients, clinically suspected to have HIT, with high titer anti‐PF4/heparin antibodies, but a negative functional test. OBJECTIVE: We investigated whether in COVID‐19 patients a serum‐derived factor inhibits the heparin‐induced platelet activation test (HIPA). METHODS AND RESULTS: 12 COVID‐19 patients with suspected HIT were tested. Three samples tested negative in all assays; nine samples tested positive by antigen tests, among which only three tested also positive by HIPA. When we spiked COVID‐19 serum or control serum with the human HIT antibody like mAb 5B9, reactivity of 5B9 remained the same. Also the purified IgG fractions of COVID‐19 sera testing strongly positive in the PF4/heparin antigen test but negative in the functional test did not show increased reactivity in the functional test in comparison to the original serum. Both results make a functionally inhibitory factor in the serum/plasma of COVID‐19 patients highly unlikely. CONCLUSION: COVID‐19 patients often present with strong reactivity in PF4/heparin antigen tests without the presence of platelet‐activating antibodies. Diagnosis of HIT requires confirmation of heparin‐dependent, platelets activating antibodies to avoid overdiagnosis and overtreatment with non‐heparin anticoagulants.

Heparin-induced thrombocytopenia (HIT) is a severe adverse reaction to heparin. Heparin forms complexes with platelet factor 4 (PF4), which induces anti-PF4/heparin IgG antibodies. When these antibodies activate platelets, this causes a prothrombotic syndrome. HIT typically occurs between day five and 14 of heparin treatment, is characterized by a decrease in platelet counts by more than 50%, and an increased risk for new thrombotic complications. [1] Diagnosis of HIT is based on clinical criteria and laboratory tests. However, diagnosis of HIT in critically ill patients is challenging. As thrombocytopenia and thrombotic complications may occur for many reasons other than HIT, [2] diagnosis strongly relies on laboratory tests for anti-PF4/heparin antibodies. Antigen tests detecting anti-PF4/heparin antibodies are widely available [3] and reliable for ruling out HIT but have limitations in confirming HIT. At best, 50% of patients with a positive anti-PF4/heparin antibody test result will also test positive in sensitive platelet activation assays, such as the serotonin-release assay (SRA) or the heparin-induced platelet activation test (HIPA). These functional tests are restricted to specialized laboratories and turn-around times of results are often longer than one day. Therefore, a high titer of anti-PF4/heparin antibodies, together with clinical symptoms suggestive for HIT, are often used for the decision to switch heparin to an alternative anticoagulant.

COVID-19 is a severe complication of coronavirus SARS-CoV-2 infection, leading to respiratory failure and the need of ventilation or even extracorporeal oxygenation (ECMO) in some patients. COVID-19 is associated with a prothrombotic state, at least in critically ill patients, [4, 5] and heparin is a cornerstone of treatment in this setting. [6, 7] Thrombocytopenia is frequent in critically ill and in intensive care unit patients, especially when extracorporeal circuits, like ECMO are required. Timing of the worsening of COVID-19, usually a week after onset of disease, overlaps with the typical time window of HIT occurrence, i.e. between day five and 14 after initiation of heparin treatment.

This article is protected by copyright. All rights reserved In patients without COVID-19, high titer anti-PF4/heparin antibodies, usually predict reasonably well a positive platelet activation test. [4, 5] We observed several COVID-19 patients with clinical symptoms suggestive of HIT and high titer anti-PF4/heparin antibodies, but a negative HIPA test. We therefore investigated whether a serum-derived factor interfering with the functional HIPA test in COVID-19 patients might be present, similar to the situation faced in patients treated with ticagrelor.

[8]

The presence of anti-PF4/heparin antibodies in serum samples was assessed by one in-house and two commercially available tests. The in-house PF4/heparin EIA was performed as described. [9] The HemosIL AcuStar-HIT IgG CLIA (Instrumentation Laboratory GmbH, Munich, Germany) and the GTI-PF4 ELISA (GTI Diagnostics, Waukesha, WI) were performed according to manufacturer's instructions.

The heparin-induced platelet activation test was performed as described. [10] Briefly, washed platelets of healthy donors were incubated with patient serum in the presence of buffer, low molecular weight heparin, reviparin 0.2 aFXaU; and unfractionated heparin 100 units. Platelet aggregation was optically assessed every five minutes.

The IgG fractions of patient and control sera were prepared using a protein G column according to standard methods. The IgG fraction was adjusted to a concentration that gave a similar OD result in the EIA as the original serum and then assessed in the HIPA test.

Monoclonal antibody 5B9 with a human Fc part recognizes PF4/heparin complexes and activates platelets in presence of low concentrations of heparin/reviparin in functional HIT tests [11] and mimics a typical human HIT antibody. Serum samples of COVID-19 patients and of a healthy control were spiked with 5B9 in concentrations from 10 to 400 µg/mL and then assessed in the HIPA test.

This article is protected by copyright. All rights reserved During the observation period from March 2020 -April 2020; 12 COVID-19 patients with suspected HIT were tested. Three samples tested negative in all assays; nine samples tested positive by antigen test among which only three tested also positive by the functional test. The usual frequency of a positive functional test in antigen test positive patients in samples referred to reference laboratories is considerably higher with about 45-50%. [12, 13] We therefore assumed that a factor in the patients' sera might inhibit the functional test. To test for the presence of an inhibitory factor in the serum of COVID-19 patients, potentially associated with false negative results in the HIPA test, we followed two approaches.

The first was to use serum samples of COVID-19 patients who tested negative or only very weakly positive (OD value <0.6; or <0.5 U/L) in the antigen assays and negative in the HIPA test and to spike them with the monoclonal antibody 5B9 in increasing concentrations. The reactivity of 5B9 remained the same, whether it was diluted in COVID-19 or control serum (table 1).

We next purified the IgG fraction of COVID-19 serum samples strongly positive in the antigen tests but negative in the HIPA test. The concentration of the purified IgG fractions was adjusted to react with a similar OD in the PF4/heparin EIA as the original sample. When tested with the HIPA, we observed no or a very weak reactivity of the IgG fraction after 20 to 30 minutes in some of the four test cells per sample (table 1) . We did not consider these reactions as reflecting the presence of typical HIT antibodies as purified IgG fractions may contain some aggregated IgG, which can alter the HIPA test.

These findings suggest that COVID-19 patients exhibit a different reactivity pattern in HIT tests compared to other patient groups. In non-COVID-19 patients, the likelihood for a positive functional test increases along OD values of the PF4/heparin EIA and the U/ml of the AcuStar HIT IgG test, [12] especially if clinical symptoms suggestive for HIT are present. [14] If the result of the AcuStar HIT-IgG is >4.00 U/mL, the likelihood ratio for the presence of platelet-activating antibodies is 47.53, and at a result of >8.00 U/mL it is 103.4.

[12] In contrast, COVID-19 patients may have strongly positive antigen tests, without plateletactivating anti-PF4/heparin antibodies. It is unlikely that this is caused by an inhibitory factor present in the serum of COVID-19 patients. An alternative explanation might be that sera which test only positive in the functional test after addition of PF4 [14] [15] [16] are prevalent in COVID-19 patients at an unusually high rate. Although we have not tested this, we regard this explanation as very unlikely. In addition, we have also excluded anti-phospholipid antibodies in these sera. Some current reports on the incidence of HIT in COVID-19 patients base their diagnosis on clinical criteria only, [17, 18] or use only anti-PF4/heparin antibody tests. [17] [18] [19] Because no functional test was used to

This article is protected by copyright. All rights reserved confirm the presence of heparin-dependent platelet-activating antibodies, these reports most likely overestimate the incidence of HIT in COVID-19. This is underscored by the findings of others. Most reports on case series of COVID 19 patients suspected to have HIT found a positive functional HIT test only in less than 35% of anti-PF4/heparin antibody positive samples (Table 2) A. Greinacher designed the study interpreted the experiments and wrote the manuscript.

All authors contributed to writing the manuscript and reviewed the final version of the manuscript. 

Heparin-Induced Thrombocytopenia

Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis

Diagnostic value of immunoassays for heparin-induced thrombocytopenia: a systematic review and meta-analysis

Venous thromboembolism in COVID-19: systematic review of reported risks and current guidelines

Incidence of venous thromboembolism in hospitalized patients with COVID-19

ISTH DIC subcommittee communication on anticoagulation in COVID-19

Thromboprophylaxis and laboratory monitoring for in-hospital patients with COVID-19 -a Swiss consensus statement by the Working Party Hemostasis

Ticagrelor causes false-negative functional tests for heparin-induced thrombocytopenia

Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia

Accuracy of heparin-induced platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia

Evaluation of functional assays for the diagnosis of heparin induced thrombocytopenia using 5B9, a monoclonal IgG that mimics human antibodies

Real-life evaluation of an automated immunoassay for diagnosis of heparin-induced thrombocytopenia

Pitfalls in the diagnosis of heparin-Induced thrombocytopenia: A 6-year experience from a reference laboratory

Combination of two complementary automated rapid assays for diagnosis of heparin-induced thrombocytopenia (HIT)

Detection of Platelet-Activating Antibodies Associated with Heparin-Induced Thrombocytopenia

Serotonin release assay (SRA)-negative HIT, a newly recognized entity: Implications for diagnosis and management

Incidence of heparin-induced thrombocytopenia in patients with

Medicina clinica

Heparin-induced thrombocytopenia is associated with a high risk of Accepted Article This article is protected by copyright. All rights reserved mortality in critical COVID-19 patients receiving heparin-involved treatment

Heparin-Induced Thrombocytopenia in Severe COVID-19

Heparin induced thrombocytopenia antibodies in Covid-19. American journal of hematology

Venous Thromboembolism Events Following Venovenous Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Syndrome Coronavirus 2 Based on CT Scans

The challenges of diagnosing heparin-induced thrombocytopenia in patients with COVID-19. Research and practice in thrombosis and haemostasis

Heparin-induced thrombocytopenia with thrombosis in COVID-19 adult respiratory distress syndrome. Research and practice in thrombosis and haemostasis

We thank Ricarda Raschke, Jessica Fuhrmann and Silvan Heeb for technical support.

AG performed consultant work for Instrumentation Laboratories. 

This article is protected by copyright. All rights reserved